Since the FDA first approved of chimeric antigen receptor (CAR) T cell therapy in 2017, Penn Medicine has had 20 additional approvals for drugs and techniques to treat or detect cancer.
The first CAR T cell therapy sparked an interest in Penn faculty to find new ways to harness the immune system to fight cancer. Faculty have also explored a wide range of other types of approaches to improve the standard of care for cancer patients. Read more here.